IBPR’s initial research for a novel anti-cancer drug-delivery system was funded by the Ministry of Economic Affairs. DBPR115 was selected as a developmental candidate and its technology transferred to Taivex Therapeutics in August 2016. The technical highlight of DBPR115 is the conjugation of Zn(II)-dipicolylamine (Zn-DPA) to the anti-cancer drug through a proprietary linker design. This patented platform provides a substantial increase of drug concentration at targeted tumor sites, increases the therapeutic index of anti-cancer drugs, reduces drug dosage, and subsequently lessens the adverse effects induced by the drug. Patent protections have been filed in several territories; the US patent was issued in July 2016.